The Food and Drug Administration (FDA) granted traditional approval to Imdelltra (tarlatamab-dlle) for adult patients with ...

1. Food and Drug Administration. FDA grants traditional approval to tarlatamab-dlle for extensive-stage small-cell lung cancer. FDA. November 19, 2025. Accessed November 19, 2025.

Amgen (NASDAQ: AMGN) announced today that the U.S. Food and Drug Administration (FDA) has granted full approval to IMDELLTRA® (tarlatamab-dlle) for the treatment of adult patients with extensive stage ...

Most lung cancer in the U.S. is diagnosed at Stage 4, after the leading cause of cancer deaths has spread to other parts of the body. However, a Maryland health system is outpacing national averages ...

For patients diagnosed with stage 4 cancer, a condition often accompanied by limited treatment options and grim prognoses, immunotherapy offers a new ray of hope. This groundbreaking approach utilizes ...

According to the NCCN Guidelines for metastatic lung cancer, standard therapies remain valuable, but they are no longer sufficient on their own. This is why molecular profiling, targeted therapy, and ...